In a BioStock Studio exclusive, Martin Welschof, CEO of BioInvent and Wei-Wu He, Chairman and CEO of the American biopharma company CASI Pharmaceuticals, joined the programme to talk about the collaboration between the two companies around the development of drug candidate BI-1206. Among other things, they discussed the reasons behind CASI chosing to partner with BioInvent, the market potential for BI-1206 and the next clinical development step for the candidate.
Watch the interview with Martin Welschof and Wei-Wu He at biostock.se:
This is a press release from BioStock - Connecting Innovation & Capital. https://www.biostock.se/